Companies
Synthego
high-quality sgRNA synthesis and turnkey cell engineering.
- Country
- United States
ISO 9001
FDA
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2012 | bondoro.com · elevenflo.com |
| Headquarters | Redwood City, CA | bondoro.com · cirm.ca.gov |
| Funding | Exceeded $450 million in total funding prior to Chapter 11 filing | bondoro.com · elevenflo.com |
| Production site | 3696 Haven Ave (Suite A and C) and 955 Charter Street, Redwood City, CA | cirm.ca.gov |
| Capacity | GMP facility (18,000+ sq ft) has 100g+ annual capacity; RUO and INDe facility (40,000+ sq ft) has 10g+ annual capacity for INDe | cirm.ca.gov |
| Certification | ISO 9001:2015 certified; GMP manufacturing adheres to FDA/ICH guidelines and ISO 13485 conditions | cirm.ca.gov · synthego.com |
| Headcount | Approximately 150 employees as of May 2025 petition date medium confidence | bondoro.com |
| Revenue | Revenue growth observed 2020-2023, but the company never reached profitability and entered Chapter 11 bankruptcy in 2025 medium confidence | bondoro.com · elevenflo.com |
Independent sources: bondoro.com · cirm.ca.gov · elevenflo.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| CRISPR screening as a service | genome-engineering | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.